[Surgical treatment of pancreatic cancer: curative resections]
- PMID: 11051689
- DOI: 10.1016/s0003-3944(00)00251-0
[Surgical treatment of pancreatic cancer: curative resections]
Abstract
Curative resection of pancreatic adenocarcinoma can only be performed in 10% of patients. This review article reports resectability rates and criteria, results of pancreatic resection and prognostic factors. Lymph node and/or vascular involvement and retroperitoneal tissue invasion constitute very poor prognostic factors; however, lymph node involvement limited to the first draining nodes and limited invasion of the mesenteric-portal vein do not constitute contraindications to surgical resection. Cephalic pancreaticoduodenectomy is still the reference procedure and its postoperative mortality has greatly decreased. The risk of pancreatic fistula mainly depends on the friability of the pancreatic stump. Median survival rate after tumour resection is usually limited between 12 and 18 months. Five-year actuarial survival rate is no more than 5%, but after curative resection (RO), it may be as high as 20 to 25% in recent surgical series. Concomitant or neoadjuvant chemotherapy-radiotherapy, currently under evaluation, may increase resection and survival rates.
Similar articles
-
Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group.Ann Surg. 1996 Feb;223(2):154-62. doi: 10.1097/00000658-199602000-00007. Ann Surg. 1996. PMID: 8597509 Free PMC article.
-
Significance of lymph node metastases in the surgical management of pancreatic head carcinoma.J Exp Clin Cancer Res. 1999 Mar;18(1):23-8. J Exp Clin Cancer Res. 1999. PMID: 10374672
-
Reassessment of the clinical significance of portal-superior mesenteric vein invasion in borderline resectable pancreatic cancer.Eur J Surg Oncol. 2017 Jun;43(6):1068-1075. doi: 10.1016/j.ejso.2017.03.020. Epub 2017 Apr 8. Eur J Surg Oncol. 2017. PMID: 28427822
-
[Surgical resection of pancreatic adenocarcinoma: indications and contraindications, pronostic factors and survival, recent advances].Cancer Radiother. 2004 Nov;8 Suppl 1:S73-9. Cancer Radiother. 2004. PMID: 15679251 Review. French.
-
[Surgery for pancreatic cancer].Z Gastroenterol. 2008 Dec;46(12):1393-403. doi: 10.1055/s-2008-1027790. Epub 2008 Dec 3. Z Gastroenterol. 2008. PMID: 19053009 Review. German.
Cited by
-
Prospective evaluation of ultrasound and colour duplex imaging for the assessment of surgical resectability of pancreatic tumours.Langenbecks Arch Surg. 2003 Dec;388(6):392-400. doi: 10.1007/s00423-003-0408-0. Epub 2003 Aug 9. Langenbecks Arch Surg. 2003. PMID: 12910422
-
Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer.BMC Cancer. 2020 Sep 23;20(1):913. doi: 10.1186/s12885-020-07420-0. BMC Cancer. 2020. PMID: 32967656 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials